Leishmaniasis Treatment Market Estimated to Record Highest CAGR by 2026

Leishmaniasis Treatment Market Estimated to
Record Highest CAGR by 2026
Leishmaniasis Treatment Market, By Disease Type (Cutaneous Leishmaniasis,
Visceral Leishmaniasis, Mucocutaneous Leishmaniasis), and By Drug Type
(Pentavalent Antimonials, Antibiotics) - Global Industry Insights, Trends,
Outlook, and Opportunity Analysis, 2018-2026
Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted
through the bite of infected female phlebotomine sand flies. According to the World Health
Organization (WHO), approximately 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur
worldwide annually due to the leishmaniasis. There are three forms of leishmaniasis namely
mucocutaneous leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis. Visceral
leishmaniasis (VL) is the most serious condition among the other two forms of leishmaniasis.
According to the World Health Organization (WHO), about 50,000 to 90,000 new cases of visceral
leishmaniasis occur worldwide annually.
According to the WHO, in 2015, more than 90% of the new cases of visceral leishmaniasis were from
Kenya, Somalia, Ethiopia, India, Brazil, Sudan, and South Sudan creating higher opportunity for
leishmaniasis treatment market. The prevalence of cutaneous leishmaniasis in the North and South
America, the Middle East, Central Asia, and Mediterranean basin is approximately 95%, according to
the WHO April 2017 factsheet. People with leishmaniasis infection develop several symptoms, such as
fever, weight loss, sores on skin, nose, mouth or throat, enlargement of spleen and liver, and abnormal
blood tests. Some patients show symptoms of anemia, leukopenia, and thrombocytopenia. Geriatric
population, infants, pregnant or lactating women, and HIV infected people have a high risk of acquiring
leishmaniasis infections, due to their weak immune systems.
Request For Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/932
Leishmaniasis disease transmission is mostly associated with unhygienic conditions, weak immune
system, and malnutrition. Increasing climatic changes and population mobility are other risk factors
associated with the leishmaniasis disease.
Depending on the degree of virulence and clinical preferences, the disease is characterized on the basis
of the type of species and subspecies of leishmania parasite. The clinical pattern of disease, the
geographic regions, and the immunological status of the patient are considered in leishmaniasis
treatment. Multiple medical treatment options are available for treatment of cutaneous leishmaniasis,
which includes parenteral and oral medications, infiltration of sodium stibogluconate at 0.3-0.8 ml,
cryotherapy, local heat therapy at 40-420C, and topical paromomycin preparations. Leishmaniasis can
be prevented by treating malnutrition, recurrent systemic infection or local infection. Tailored disease
management for treating leishmaniasis is expected to have a potential for improving leishmaniasis
treatment market in near future.
Introduction of new chemical entity will drive the leishmaniasis treatment market
According to data published in 2017, by Drugs for Neglected Diseases initiative (DNDi’), two new
chemical entities (NCE) DNDI-6148 and DNDI-0690 are introduced into the preclinical development
stage to treat visceral and cutaneous leishmaniasis in 2016. Immunomodulator- CpG-D35, is also in
pre-clinical development stage, which will be used as an adjunct along with drug therapy to fight
cutaneous leishmaniasis. These advances have the potential to transform drug development into new
treatment therapy in near future, in turn driving the growth of leishmaniasis treatment market.
Key Players in the Leishmaniasis treatment market
Key players operating in the leishmaniasis treatment market include Sanofi S.A., Sequus
Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, and
Lifecare Innovations Private Limited.
Get The PDF Brochure of This Report @
https://www.coherentmarketinsights.com/insight/request-pdf/932
Combined agreement between WHO and Gilead Sciences, Inc. will expand leishmaniasis
treatment market
In 2016, the World Health Organization (WHO) and Gilead Sciences, Inc. signed an agreement to
donate 3,80,400 vials of AmBisome (liposomal amphotericin B), extending their previous agreement
from 2016 to 2021. The five year collaboration and funding of US$ 20 million by Gilead Sciences, Inc.
are intended to provide access to diagnosis and treatment to the populations affected by visceral
leishmaniasis in key endemic countries such as Ethiopia, India, Nepal, Bangladesh, South Sudan, and
Sudan. Financial contribution made by Gilead Sciences, Inc. helped WHO to expand, control, and
reinforce surveillance in many endemic countries.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted through the bite of infected female phlebotomine sand flies. According to the World Health Organization (WHO), approximately 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur worldwide annually due to the leishmaniasis.

Download Report